DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Weiss J. et al
Progression-free survival, overall survival, and immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated with definitive radiotherapy plus pembrolizumab..
MHNCS 2020 Abstract LBA 1
Access:
We do not assume any responsibility for the contents of the web pages of other providers.